Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Johns Hopkins University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00806676
First received: December 9, 2008
Last updated: May 25, 2010
Last verified: May 2010
  Purpose

People with chronic kidney disease are known to have immune response abnormalities, including a diminished response to some vaccinations. Those with chronic kidney disease have a disproportionate burden of HPV 6-, 11-, 16- and/or 18-related genital tract disease. Due to immune response abnormalities, the CKD population may or may not respond to the recommended three-dose regimen of Gardasil®, a vaccine intended to protect against HPV 6-, 11-, 16-, and 18-related genital tract disease. The objective of this study is to measure the antibody response to Gardasil® in female patients 9-21 years of age with chronic kidney disease (CKD) (Stage 1-4), end-stage kidney disease (Stage 5 CKD), and status-post kidney transplant. Gardasil® vaccine will be administered according to the FDA-approved schedule. Blood samples to measure antibody levels to vaccine strains of human papillomavirus (HPV) will be obtained at months 0, 7 and 24.


Condition Intervention
Chronic Kidney Disease
Drug: Gardasil® Vaccine (FDA-approved vaccination regimen)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Geometric mean antibody titers to HPV 6, 11, 16 and 18. [ Time Frame: Baseline, Months 7 and 24 ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2008
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1. Chronic Kidney Disease, NKF Stage 1-4
Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
Drug: Gardasil® Vaccine (FDA-approved vaccination regimen)
Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
2. ESRD (dialysis)
Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
Drug: Gardasil® Vaccine (FDA-approved vaccination regimen)
Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
3. Kidney Transplant Recipient
Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
Drug: Gardasil® Vaccine (FDA-approved vaccination regimen)
Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.

  Eligibility

Ages Eligible for Study:   9 Years to 21 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Females, aged 9-21 years, in the following groups:

  • CKD (defined as estimated glomerular filtration rate between 90 ml/min/1.73m2 and 15 ml/min/1.73m2, as calculated by the Schwartz formula)
  • ESRD (eGFR < 15 ml/min/1.73m2, or receiving chronic dialysis [peritoneal or hemodialysis])
  • Status-post kidney transplant

Exclusion Criteria:

  • Within first 3 months post kidney transplant
  • Within 3 months of kidney rejection episode
  • Hypersensitivity to active substances or excipients of Gardasil vaccine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00806676

Contacts
Contact: Jeffrey J Fadrowski, MD, MHS 410-955-2467 jfadrow1@jhmi.edu

Locations
United States, Georgia
Emory Healthcare & Children's Healthcare of Atlanta Pediatric Nephrology Clinic Recruiting
Atlanta, Georgia, United States, 30322
Contact: Sandra G Amaral, MD, MHS    404-727-8213    sandra_amaral@oz.ped.emory.edu   
Principal Investigator: Sandra G Amaral, MD, MHS         
United States, Maryland
Johns Hopkins University Harriet Lane Kidney Center, Rubenstein Child Health Bldg Recruiting
Baltimore, Maryland, United States, 21287
Contact: Jeffrey J Fadrowski, MD, MHS    410-955-2467    jfadrow1@jhmi.edu   
Contact: Katie Alcorn, BA    443-287-5393    kalcorn1@jhmi.edu   
Principal Investigator: Jeffrey J Fadrowski, MD, MHS         
Sponsors and Collaborators
Johns Hopkins University
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Jeffrey J Fadrowski, MD, MHS Johns Hopkins University
  More Information

No publications provided

Responsible Party: Jeffrey Fadrowski MD, MHS/Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine
ClinicalTrials.gov Identifier: NCT00806676     History of Changes
Other Study ID Numbers: MERCK_33610
Study First Received: December 9, 2008
Last Updated: May 25, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:
chronic kidney disease
children
dialysis
kidney transplant
human papilloma virus
Gardasil
Chronic kidney disease (non-dialysis, dialysis, and kidney transplant) secondary to any cause.

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Urologic Diseases
Antibodies
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014